Schulz WA - Search Results

1

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.

Skowron MA, Melnikova M, van Roermund JGH, Romano A, Albers P, Thomale J, Schulz WA, Niegisch G, Hoffmann MJ. Skowron MA, et al. Among authors: schulz wa. Int J Mol Sci. 2018 Feb 16;19(2):590. doi: 10.3390/ijms19020590. Int J Mol Sci. 2018. PMID: 29462944 Free PMC article.

2

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.

Heubach J, Monsior J, Deenen R, Niegisch G, Szarvas T, Niedworok C, Schulz WA, Hoffmann MJ. Heubach J, et al. Among authors: schulz wa. Mol Cancer. 2015 May 21;14:108. doi: 10.1186/s12943-015-0371-8. Mol Cancer. 2015. PMID: 25994132 Free PMC article.

3

Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.

Knievel J, Schulz WA, Greife A, Hader C, Lübke T, Schmitz I, Albers P, Niegisch G. Knievel J, et al. Among authors: schulz wa. Int J Mol Sci. 2014 Nov 7;15(11):20500-17. doi: 10.3390/ijms151120500. Int J Mol Sci. 2014. PMID: 25387078 Free PMC article.

4

Epigenetics of urothelial carcinoma.

Schulz WA, Koutsogiannouli EA, Niegisch G, Hoffmann MJ. Schulz WA, et al. Methods Mol Biol. 2015;1238:183-215. doi: 10.1007/978-1-4939-1804-1_10. Methods Mol Biol. 2015. PMID: 25421661 Review.

5

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.

Skowron MA, Niegisch G, Fritz G, Arent T, van Roermund JG, Romano A, Albers P, Schulz WA, Hoffmann MJ. Skowron MA, et al. Among authors: schulz wa. J Exp Clin Cancer Res. 2015 Nov 25;34:144. doi: 10.1186/s13046-015-0259-x. J Exp Clin Cancer Res. 2015. PMID: 26606927 Free PMC article.

6

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.

Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA, Niegisch G. Pinkerneil M, et al. Among authors: schulz wa. Mol Cancer Ther. 2016 Feb;15(2):299-312. doi: 10.1158/1535-7163.MCT-15-0618. Epub 2016 Jan 15. Mol Cancer Ther. 2016. PMID: 26772204

7

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.

Höhn A, Krüger K, Skowron MA, Bormann S, Schumacher L, Schulz WA, Hoffmann MJ, Niegisch G, Fritz G. Höhn A, et al. Among authors: schulz wa. Oncotarget. 2016 Jul 5;7(27):41320-41335. doi: 10.18632/oncotarget.9321. Oncotarget. 2016. PMID: 27191498 Free PMC article.

8

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.

Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G. Pinkerneil M, et al. Among authors: schulz wa. Target Oncol. 2016 Dec;11(6):783-798. doi: 10.1007/s11523-016-0444-7. Target Oncol. 2016. PMID: 27250763 Free PMC article.

9

Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells.

Koutsogiannouli EA, Wagner N, Hader C, Pinkerneil M, Hoffmann MJ, Schulz WA. Koutsogiannouli EA, et al. Among authors: schulz wa. Int J Mol Sci. 2017 Jul 5;18(7):1449. doi: 10.3390/ijms18071449. Int J Mol Sci. 2017. PMID: 28678170 Free PMC article.

10

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.

Skowron MA, Niegisch G, Albrecht P, van Koeveringe G, Romano A, Albers P, Schulz WA, Hoffmann MJ. Skowron MA, et al. Among authors: schulz wa. Int J Mol Sci. 2017 Aug 2;18(8):1680. doi: 10.3390/ijms18081680. Int J Mol Sci. 2017. PMID: 28767070 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters